Company Acknowledgement. The Company acknowledges that the Offering of convertible Securities may create significant risks, including the risk that the Company may have insufficient cash resources and/or registered shares to timely meet its payment and conversion obligations. The Company further acknowledges that, depending on the number and price of new shares issued, such transaction may result in substantial dilution which could adversely affect the market price of the Company’s shares.
Appears in 16 contracts
Samples: Placement Agent Agreement (Rexahn Pharmaceuticals, Inc.), Placement Agent Agreement (Rexahn Pharmaceuticals, Inc.), Placement Agent Agreement (Adventrx Pharmaceuticals Inc)
Company Acknowledgement. The Company acknowledges that the Offering of convertible Securities may create significant risks, including the risk that the Company may have insufficient cash resources and/or registered shares to timely meet its payment and conversion obligations. The Company further acknowledges that, depending on the number and price of new shares issued, such transaction may result in substantial dilution which could adversely affect effect the market price of the Company’s 's shares.
Appears in 1 contract
Company Acknowledgement. The Company acknowledges that the Offering Placement of convertible Securities may create significant risks, including the risk that the Company may have insufficient cash resources and/or registered shares to timely meet its payment and conversion obligations. The Company further acknowledges that, depending on the number and price of new shares issued, such transaction may result in substantial dilution which could adversely affect the market price of the Company’s shares.
Appears in 1 contract
Samples: Placement Agent Agreement (Adventrx Pharmaceuticals Inc)
